Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (Q34383685)

1 August 2017

Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease (English)

1 reference

1 August 2017

0 references

John J McMurray

11

0 references

Giuseppe Remuzzi

object named as

Giuseppe Remuzzi

14

0 references

Janet Wittes

18

object named as

Janet Wittes

1 reference

1 August 2017

13

Hans-Henrik Parving

1 reference

1 August 2017

15

Robert D Toto

1 reference

1 August 2017

2

Tadao Akizawa

1 reference

1 August 2017

3

Paul Audhya

1 reference

1 August 2017

4

George L Bakris

1 reference

1 August 2017

5

Melanie Chin

1 reference

1 August 2017

6

Heidi Christ-Schmidt

1 reference

1 August 2017

7

Angie Goldsberry

1 reference

1 August 2017

9

Melissa Krauth

1 reference

1 August 2017

10

Hiddo J Lambers Heerspink

1 reference

1 August 2017

12

Colin J Meyer

1 reference

1 August 2017

16

Nosratola D Vaziri

1 reference

1 August 2017

19

Danielle Wrolstad

1 reference

1 August 2017

20

Glenn M Chertow

1 reference

1 August 2017

Dick de Zeeuw

1

1 reference

1 August 2017

Mark Houser

8

1 reference

1 August 2017

Christoph Wanner

17

1 reference

1 August 2017

BEACON Trial Investigators

21

1 reference

1 August 2017

language of work or name

English

0 references

publication date

9 November 2013

1 reference

The New England Journal of Medicine

1 August 2017

1 reference

1 August 2017

369

1 reference

1 August 2017

2492-2503

1 reference

1 August 2017

26

1 reference

Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON).

1 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney disease

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Cardiorenal end points in a trial of aliskiren for type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl decreases megalin and activates nrf2 in the kidney

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The kidney in type 2 diabetes therapy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Sulodexide fails to demonstrate renoprotection in overt type 2 diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic-acid methyl ester has potent anti-diabetic effects in diet-induced diabetic mice and Lepr(db/db) mice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Avosentan for overt diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Combined angiotensin inhibition for the treatment of diabetic nephropathy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Bardoxolone methyl analogs RTA 405 and dh404 are well tolerated and exhibit efficacy in rodent models of Type 2 diabetes and obesity.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

The Effects of Dietary Protein Restriction and Blood-Pressure Control on the Progression of Chronic Renal Disease

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4496027

Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy

9 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24206459

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24206459

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1306033

1 reference

1 August 2017

1 reference

1 August 2017

1 reference